ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGFR2-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGFR2-inhibitor
8
trial(s) found.
NCT06082167
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (
STELLAR-305
)
MET/VEGFR2/AXL/MER inhibitor
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05678673
Advanced
Phase 3
Recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (
STELLAR-304
)
KIT inhibitor,first generation
MET/VEGFR2/AXL/MER inhibitor
PDGFR inhibitor
VEGFR inhibitor
anti-PD-1 monoclonal antibody
Non-clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ VEGFR2 inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12619001655134
Haem
Phase 2
Recruiting
AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (
INTERVENE
) Acute Myeloid Leukaemia
BCL2 inhibitor
+ VEGFR2 inhibitor
Acute myeloid leukaemia
NCT05425940
Advanced
Phase 3
Active not recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (
STELLAR-303
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
MET/VEGFR2/AXL/MER inhibitor
anti-PD-L1 monoclonal antibody
Colorectal cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT03685448
Advanced
Phase 2
Unknown
A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802) (
UNICAB
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
Xp11 translocation renal carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT03170960
Advanced
Phase 1 / Phase 2
Unknown
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (
XL184-021
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-PD-L1 monoclonal antibody
Differentiated thyroid carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Unknown (2)
Enrolling by invitation (1)
Active not recruiting (1)
Recruitment Country and State
NSW (7)
SA (6)
VIC (6)
QLD (3)
NZ (2)
WA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (2)
Phase 2 / Phase 3 (1)
Phase 3 (3)
Trial Type
Advanced (7)
Haem (1)
Cancer Therapy Class
VEGFR2
100%
KIT
88%
AXL
75%
MET
75%
PD-1/PD-L1
75%
VEGFR
75%
RET
63%
PD-1
50%
PDGFR
50%
MER
38%
ROS1
38%
PD-L1
25%
HIF2a
13%
ERBB2
13%
HPK1
13%
LAG3
13%
OX40
13%
PARP
13%
TIGIT
13%
VEGF
13%
VEGFR1
13%
VEGFR3
13%
BCL2
13%
FLT3
13%
HDAC
13%
PKC
13%
FGFR
13%
FGFR1
13%
FGFR1/2/3
13%
FGFR2
13%
FGFR3
13%
FGFR4
13%
AR
13%
CYP17A1
13%
androgen axis
13%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (4)
2109 - North Ryde - Macquarie University Hospital (4)
5042 - Bedford Park - Flinders Medical Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5037 - Glandore - Ashford Cancer Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2217 - Kogarah - St George Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
Cancer Type
Cancer
Solid tumour
Kidney cancer
Urogenital cancer
Non-clear cell renal cell carcinoma
Clear cell renal cell carcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Acute myeloid leukaemia
Haematological malignancy
Leukaemia
Myeloid leukaemia
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Chromophobe renal cell carcinoma
Papillary renal cell carcinoma
Sarcomatoid renal cell carcinoma
Type 1 papillary renal cell carcinoma
Type 2 papillary renal cell carcinoma
Xp11 translocation renal carcinoma
Differentiated thyroid carcinoma
Endocrine gland cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy